Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Pharmacological modulation of the GABA A receptor has gained increasing attention as a potential treatment for central processes affected in Alzheimer disease (AD), including neuronal survival and cognition. The proteolytic cleavage of the amyloid precursor protein (APP) through the α‐secretase pathway decreases in AD, concurrent with cognitive impairment. This APP cleavage occurs within the β‐amyloid peptide (Aβ) sequence, precluding formation of amyloidogenic peptides and leading to the release of the soluble N‐terminal APP fragment (sAPPα) which is neurotrophic and procognitive. In this study, we show that at nanomolar‐low micromolar concentrations, etazolate, a selective GABA A receptor modulator, stimulates sAPPα production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM–2 μM) dose‐dependently protected rat cortical neurons against Aβ‐induced toxicity. The neuroprotective effects of etazolate were fully blocked by GABA A receptor antagonists indicating that this neuroprotection was due to GABA A receptor signalling. Baclofen, a GABA B receptor agonist failed to inhibit the Aβ‐induced neuronal death. Furthermore, both pharmacological α‐secretase pathway inhibition and sAPPα immunoneutralization approaches prevented etazolate neuroprotection against Aβ, indicating that etazolate exerts its neuroprotective effect via sAPPα induction. Our findings therefore indicate a relationship between GABA A receptor signalling, the α‐secretase pathway and neuroprotection, documenting a new therapeutic approach for AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 1×
“By stimulating cAMP levels, the PDE4 inhibitor Rolipram and the PDE4CREB pathway show beneficial effect at counteracting Abinduced memory, synaptic and dendritic alterations (Gong et al. 2004; Shrestha et al. 2006).”
BackgroundRing, S., Weyer, S. W., Kilian, S. B., Waldron, E., Pietrzik, C. U., Filippov, M. A., Herms, J., Buchholz, C., Eckman, C. B., Korte, M., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1026-07.2007 · Cited by 390 · cited 1×
“…stimulates long-term potentiation (LTP), which is a candidate cellular mechanism for learning and memory, has potent memory-enhancing effects (Meziane et al. 1998; Ring et al. 2007) and plays a role in the promotion of neurite outgrowth, synaptogenesis and synaptic plasticity (Turner et al. 2003).”
BackgroundSynaptic Changes in Alzheimer's Disease
Gylys, K. H., Fein, J. A., Yang, F., Wiley, D. J., Miller, C. A., & Cole, G. M. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63436-0 · Cited by 253
Nitsch, R. M., Farber, S. A., Growdon, J. H., & Wurtman, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5191 · Cited by 244
Lanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900705 · Cited by 191
Kojro, E., Postina, R., Buro, C., Meiringer, C., Gehrig‐Burger, K., & Fahrenholz, F. (2006) · The FASEB Journal · doi:10.1096/fj.05-4812fje · Cited by 118 · cited 1×
“A number of studies indicate that an increase in activity of a-secretases, particularly ADAM10, in the brain of AD patients may be achieved by modulating selective signaling pathways that increase their activity or expression level (Hashimoto et al. 2003; Robert et al. 2005; Kojro et al. 2006).”
Background
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
APP processing in Alzheimer’s disease.
Zhang, Y.-W., Thompson, R., Zhang, H., & Xu, H. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-3 · Cited by 983
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376
Metadata
- Authors
- Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2008-04-05
- Volume
- 106
- Issue
- 1
- Pages
- 392-404
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2002305576
- Cited by
- 154
- References
- 10
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. https://app.cochat.ai/papers/10.1111/j.1471-4159.2008.05396.x
- The paper
- Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008). Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2008.05396.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.